New Drug Targets Neuropathic Pain
A new drug developed by Tel Aviv University researchers has been licensed by pharmaceutical company BioLineRx and offers a new treatment option to patients with neuropathic pain.
Developed by Bernard Attali and Asher Peretz, MD, of the Sackler Faculty of Medicine, the medication, known as BL-7050, inhibits the transmission of pain signals throughout the body. In experiments measuring electrical activity of neurons, the drug has been shown to prevent the hyper-excitability of neurons, protecting against neuropathic pain and epileptic seizures.
Related Articles on Pain Management:
Study Sheds Doubt on Steroid Injections for Back PainWisconsin to Have Statewide Drug Monitoring System
Most Patients Take Incorrect Dosages of Prescription Drugs
© Copyright ASC COMMUNICATIONS 2012. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
© Copyright ASC COMMUNICATIONS 2012. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
Latest Articles
- Senate Introduces Companion Medicare RAC Reform Bill
- Drs. Brian Cole, Anthony Romeo of Midwest Orthopaedics at Rush Among Top Orthopedic Surgeons Contributing to Orthopedic Literature
- Spinal Elements Upgrades to 40,000-Square-Foot Headquarters
- UnitedHealth, Aetna, Cigna to Sit Out of California's Health Insurance Exchange
- Rhode Island Nixes "Confidential" Prices Between Payors, Providers